The lawsuit claims that three major healthcare companies were pushing up the price of insulin by 1,200 percent.

Regulators published their most detailed findings yet on how some of the nation’s largest companies profited from "excess" ...

Agency commissioners voted unanimously on Tuesday to publish the report, which makes similar allegations against the ...

Units of CVS Health Corp., Cigna Group and UnitedHealth Group Inc. charged significantly more than the national average ...

The Federal Trade Commission accused UnitedHealth's OptumRx, CVS Caremark, and Cigna's Express Scripts of pocketing over $7 ...

The FTC report found that from 2017 to 2022, three PBMs—UnitedHealth Group's Optum, CVS Health's CVS Caremark and Cigna's ...

From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 billion in revenue.

The Federal Trade Commission voted unanimously to release additional findings from its yearslong probe into CVS Caremark, ...

Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in ...